🔗 Share this article

While America proceeds with sweeping adjustments to its vaccine guidelines, one figure has surfaced unexpectedly: Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by questioning Covid vaccines during the pandemic and has concentrated on alleged deaths after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Schedule

Health officials were set to announce sweeping changes to the childhood immunization program earlier this month, aligning the US with the Danish immunization schedule, according to reports – a major change that would put the US out of alignment with many the world with little proof for public health gain. The announcement has been delayed until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to address the audience at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this calendar year.

A Shift at the Agency

The acting appointment might represent a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it points to a greater focus upon dismantling previously authorized vaccines at the FDA.

Høeg has repeatedly called for ending certain pediatric shot schedules in the US in order to be more in line with Denmark, a society with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – usually the domain of Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Høeg has little discernible background in medication creation, oversight or management, which has been typical for former directors of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“She appears not to have the necessary background” for running the CDER, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in managing a sizeable institution. She is not an expert in drug approvals.”

Former commissioners of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she lacks the kind of background that former directors who ran CBER have had.”

CDER has an immense portfolio at the FDA, Woodcock pointed out.

“Many people just zeroes in on the new drug program, but the generic program clears a multitude of generic medications. There is also a biosimilars program, over-the-counter program and so forth, and each of these need to be managed,” Woodcock noted. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a significant administrative component to the role, which oversees over 5,000 staff members. “It is a massive leadership role, if you execute it properly,” she said.

Agency Reaction and Contentious Initiatives

When asked about inquiries about Høeg’s credentials and whether this assignment represents greater collaboration among FDA leaders on vaccines, a representative responded that the “inquiries are based on flawed premises”.

“Her experience aligns with the duties of her role,” the representative explained, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s controversial expedited review system, a controversial expedited medication authorization process that allegedly worried her preceding directors. “By what process are these drugs being selected for this fast-track system? Who makes the decisions?” Howard questioned. “There is a lot of confidentiality occurring at the agency right now.”

In general, he said, “the FDA looks to be trending towards laxer rules of pharmaceuticals, aside from shots.”

Public History on Immunizations

Concerning vaccines, Høeg has a more established, if problematic, past, some experts said. She released a research paper using non-validated public submissions to assess the frequency of myocarditis following COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “desired changes” for the incoming administration included changing regulations for recently developed shots and halting “non-essential” vaccines, she said after the election on a online show. At the agency, Høeg has allegedly floated the idea of excluding teenage boys from receiving COVID-19 vaccinations.

“She is an thorough true believer who begins with her preconceived notions and works backwards to retrofit the science in a extremely disingenuous, untruthful manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|